Romidepsin Side Effects: Safety Signals and Warnings
Romidepsin safety concerns are compound-specific. The main listed side effects are Nausea and vomiting, Fatigue, and Thrombocytopenia. The main warning signals are ECG monitoring required - QT prolongation risk, Electrolyte abnormalities must be corrected before dosing, and Tumor lysis syndrome risk in patients with high tumor burden.
Direct Answer
Romidepsin (Istodax) is FDA-approved for cutaneous T-cell lymphoma and peripheral T-cell lymphoma with Phase 2/3 data supporting meaningful response rates in these difficult-to-treat malignancies. As a bicyclic depsipeptide HDAC inhibitor, it has a unique cyclopeptide structure within its drug class. A well-validated niche oncology drug with a defined patient population.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Immune Support
- Best for
- Cutaneous T-cell lymphoma, peripheral T-cell lymphoma, HDAC inhibitor pharmacology research
Reported Side Effects
- Nausea and vomiting
- Fatigue
- Thrombocytopenia
- ECG changes (T-wave, ST-segment)
- Dysgeusia (altered taste)
- Infections
Warnings
- ECG monitoring required - QT prolongation risk
- Electrolyte abnormalities must be corrected before dosing
- Tumor lysis syndrome risk in patients with high tumor burden
- Myelosuppression - monitor complete blood counts regularly
Known or Plausible Interactions
- QT-prolonging drugs (additive cardiac risk)
- CYP3A4 inhibitors (may increase romidepsin levels)
- Warfarin (INR changes reported)
- Rifampin and other CYP3A4 inducers (may reduce efficacy)
Regulatory Context
FDA-approved for cutaneous T-cell lymphoma (2009) and peripheral T-cell lymphoma (2011). Available by prescription only. Marketed as Istodax by Celgene/Bristol-Myers Squibb.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Cutaneous T-Cell Lymphoma (Level A), Peripheral T-Cell Lymphoma (Level A), and Cardiac Effects (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Romidepsin Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/romidepsin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.